

Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats

*Shyam H. Kamble^{†, ‡}, Erin C. Berthold[†], Tamara I. King[†], Siva Rama Raju Kanumuri^{†, ‡}, Raluca Popa[†], Julius R. Herting[†], Francisco León^{§, 1}, Abhisheak Sharma^{†, ‡}, Lance R. McMahon[^], Bonnie A. Avery^{†, ‡}, and Christopher R. McCurdy^{†, ‡, §, *}*

[†]Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL,
USA

[‡]Translational Drug Development Core, Clinical and Translational Sciences Institute, University
of Florida, Gainesville, FL, USA

[§]Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville,
FL, USA

[^]Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville,
FL, USA

¹Current address: Department of Drug Discovery and Biomedical Science, College of Pharmacy, University of South Carolina, Columbia, SC, USA

➤ **Preparation of lyophilized kratom tea (LKT)**

The dried leaves material of *Mitragyna speciosa* (kratom) were purchased from “Pure Land Ethnobotanicals” and authenticated by Dr. Rita Moraes from the National Center for Natural Products Research, School of Pharmacy, University of Mississippi. The dried leaf powder samples (200 g) were placed in a 2.8 L conical flask, previously filled with boiling water at 100 °C and boiled for approximately 20 minutes. The mixture was then cooled and filtered using fine tea mesh. The volume of the tea was reduced to one third using a rotavapor, followed by being completely dried on a lyophilizer (Labconco® 2.5 L free zone) overnight to produce 22 g of LKT.

Table S1: The recovery and matrix effect of each kratom alkaloids in rat plasma

| Analyte | Recovery | | | | Matrix effect | | | |
|---------|-------------|-------------|------------|------------|---------------|-------------|------------|------------|
| | LLQC | LQC | MQC | HQC | LLQC | LQC | MQC | HQC |
| MTG | 109.1 ± 4.0 | 104.5 ± 4.9 | 97.8 ± 5.6 | 98.5 ± 6.8 | 96.6 ± 3.4 | 95.1 ± 6.7 | 91.7 ± 5.4 | 89.2 ± 5.9 |
| 7-HMG | 91.6 ± 7.3 | 92.2 ± 9.3 | 97 ± 5.3 | 97.7 ± 7.9 | 91.7 ± 9 | 91.3 ± 9.4 | 88.6 ± 5.2 | 85.9 ± 5.8 |
| COR | 102 ± 8.6 | 96.9 ± 3.2 | 96.3 ± 5.3 | 96.7 ± 7.1 | 90.9 ± 9.5 | 91.4 ± 5.7 | 89.6 ± 4.8 | 87.6 ± 5.8 |
| SPG | 94.3 ± 10.3 | 95.3 ± 3.4 | 96.8 ± 4.7 | 97.7 ± 7.1 | 89.8 ± 7.8 | 92.1 ± 6.8 | 90.7 ± 5.2 | 88.4 ± 6.3 |
| SPC | 94.5 ± 2.4 | 94.7 ± 5.1 | 96.7 ± 6.1 | 97.6 ± 6.8 | 111.6 ± 12.4 | 101.9 ± 4 | 90.5 ± 5.7 | 88.4 ± 5.7 |
| PAY | 103.4 ± 6.4 | 98.6 ± 2.7 | 97 ± 5.8 | 96.8 ± 7.8 | 91.2 ± 4.2 | 92.8 ± 6.2 | 90.1 ± 5.5 | 88.1 ± 6.1 |
| COX | 97.8 ± 8.9 | 104 ± 6.6 | 96.9 ± 5.7 | 97.2 ± 8.2 | 93.2 ± 16.5 | 90.5 ± 8.6 | 88.7 ± 6.6 | 86.3 ± 6.6 |
| COX-B | 96.3 ± 5.1 | 97 ± 5.3 | 97.2 ± 7.1 | 96.8 ± 6 | 79.9 ± 5.1 | 89.1 ± 10.9 | 84.8 ± 5.8 | 82.9 ± 6.1 |
| AJM | 100.5 ± 7.9 | 93.4 ± 3.8 | 95.5 ± 7 | 95.4 ± 7.2 | 88.4 ± 9.8 | 92.4 ± 4.7 | 86.1 ± 6.3 | 83.8 ± 6.4 |
| MTP | 95 ± 7.9 | 94.9 ± 4.6 | 97.4 ± 6.5 | 97.3 ± 8.3 | 95.8 ± 10.6 | 98.7 ± 9.1 | 97.1 ± 5.7 | 93.4 ± 6.9 |
| i-SPF | 99.8 ± 9.1 | 93.1 ± 10.1 | 95.9 ± 5.6 | 95.8 ± 7.2 | 87.8 ± 10.1 | 91.7 ± 6.5 | 90.6 ± 6.1 | 87.4 ± 6.4 |

The values represent mean ± S.D. (n = 6). The recovery was calculated as % ratio of the analyte peak area in pre-spiked to post-spiked rat plasma samples. The matrix effect was calculated as the % ratio of the analyte peak area of the post-spiked plasma sample to the aqueous QC standard samples.

Table S2. Individual and relative alkaloid content in OPMS liquid and lyophilized kratom tea (LKT)

| Kratom products | Individual alkaloids | | | | | | | | | | |
|--|----------------------|-------|------|------|------|------|-----|-------|-----|-----|-------|
| | MTG | 7-HMG | COR | SPG | SPC | PAY | COX | COX-B | MTP | AJM | i-SPF |
| OPMS liquid (mg/ml) | 11.81 | BLQ | BLQ | 1.51 | 2.76 | 2.17 | BLQ | 0.67 | BLQ | BLQ | 0.84 |
| Relative alkaloid content in OPMS liquid normalized to mitragynine | 1.00 | NA | NA | 0.13 | 0.23 | 0.18 | NA | 0.06 | NA | NA | 0.07 |
| LKT (% w/w) | 1.57 | BLQ | 0.04 | 0.22 | 0.56 | 0.30 | BLQ | 0.04 | BLQ | BLQ | BLQ |
| Relative alkaloid content in LKT normalized to mitragynine | 1.00 | NA | 0.03 | 0.14 | 0.36 | 0.19 | NA | 0.03 | NA | NA | NA |

BLQ: below the lower limit of quantification (0.03 mg/ml for OPMS liquid and 0.02% w/w for LKT), NA: Not applicable

Table S3: Source parameters for kratom alkaloids and internal standard

| Sr. No. | Alkaloids | Ion transition (m/z) | Cone voltage (V) | Collision energy (V) |
|----------------|----------------------|-----------------------------|-------------------------|-----------------------------|
| 1 | Mitragynine | 399.2 > 174.2 | 60 | 32 |
| 2 | 7-Hydroxymitragynine | 415.2 > 190.1 | 42 | 30 |
| 3 | Corynantheidine | 369.2 > 144.1 | 46 | 32 |
| 4 | Speciogynine | 399.2 > 174.2 | 60 | 32 |
| 5 | Speciociliatine | 399.2 > 174.2 | 60 | 32 |
| 6 | Paynantheine | 397.2 > 174.2 | 58 | 30 |
| 7 | Corynoxine | 385.2 > 132.1 | 26 | 44 |
| 8 | Corynoxine-B | 385.2 > 132.1 | 26 | 44 |
| 9 | Mitraphylline | 369.3 > 160.1 | 2 | 30 |
| 10 | Ajmalicine | 352.9 > 144.0 | 68 | 28 |
| 11 | Isospeciofoline | 401.1 > 257.1 | 2 | 30 |
| 12 | Verapamil (IS) | 455.3 > 150.1 | 28 | 42 |